Innate Pharma (IPHA) Change in Cash (2020 - 2024)
Historic Change in Cash for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to -$4.5 million.
- Innate Pharma's Change in Cash rose 6930.56% to -$4.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$76.9 million, marking a year-over-year increase of 4915.2%. This contributed to the annual value of -$4.6 million for FY2024, which is 6907.69% up from last year.
- Innate Pharma's Change in Cash amounted to -$4.5 million in Q4 2024, which was up 6930.56% from -$14.7 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Change in Cash ranged from a high of -$4.5 million in Q4 2024 and a low of -$78.8 million during Q4 2020
- In the last 5 years, Innate Pharma's Change in Cash had a median value of -$19.9 million in 2022 and averaged -$31.1 million.
- As far as peak fluctuations go, Innate Pharma's Change in Cash soared by 2646.72% in 2023, and later surged by 6930.56% in 2024.
- Over the past 5 years, Innate Pharma's Change in Cash (Quarter) stood at -$78.8 million in 2020, then skyrocketed by 52.04% to -$37.8 million in 2021, then surged by 47.27% to -$19.9 million in 2022, then increased by 26.47% to -$14.7 million in 2023, then skyrocketed by 69.31% to -$4.5 million in 2024.
- Its Change in Cash was -$4.5 million in Q4 2024, compared to -$14.7 million in Q4 2023 and -$19.9 million in Q4 2022.